NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Mirador Therapeutics

Mirador Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://www.miradortx.com/

Last Round

Series B

Jan 12, 2026

Total Funding Raised

$1.15B

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Mirador Therapeutics is a biotechnology company that develops precision medicines for immune-mediated inflammatory and fibrotic diseases using its proprietary Mirador360™ discovery and development engine.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

precision medicinedrug discoverybiotechimmuno-fibrotic diseasetarget identificationAI drug discoveryclinical pipelinegenomicspatient stratificationtherapeutic developmentin-silico discoverybiotech startupdrug development platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mirador Therapeutics Comparables

Compare Mirador Therapeutics with similar companies based on industry and business-model similarity.

Mirador Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Insitro
82%
Seismic
82%
Odyssey Therapeutics
81%

Mirador Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 12, 2026
Series BSep 30, 2025
Series AMar 21, 2024

Mirador Therapeutics Investors

Notable investors and investment history

Mirador Therapeutics investors
InvestorRounds
Farallon Capital ManagementSeries B, Series A
TCG CrossoverSeries B, Series A
Boxer CapitalSeries B, Series A
Fairmount Funds ManagementSeries B, Series A
ARCH Venture PartnersSeries B, Series A
Fidelity Management & Research CompanySeries B, Series A
Blue Owl CapitalSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 12, 2026

    $250M round with participation from Venrock and Adage Capital.

  • Jan 1, 2026

    Certified as a Great Place To Work®.

Mirador Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mirador Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mirador Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range98
Year Founded2024
Last FundingJan 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.